What is Wedbush’s Estimate for STOK Q1 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush issued their Q1 2026 earnings per share estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, May 13th. Wedbush analyst L. Chico anticipates that the company will earn ($0.64) per share for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.73) EPS and Q4 2026 earnings at ($0.75) EPS.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

A number of other equities research analysts also recently issued reports on the company. HC Wainwright cut their price target on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Cantor Fitzgerald upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday. Finally, Chardan Capital restated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $23.20.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $9.76 on Thursday. Stoke Therapeutics has a one year low of $5.35 and a one year high of $17.58. The business’s fifty day moving average is $8.16 and its 200 day moving average is $9.98. The stock has a market capitalization of $532.87 million, a PE ratio of -4.65 and a beta of 1.20.

Institutional Trading of Stoke Therapeutics

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its stake in Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock valued at $36,000 after buying an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Stoke Therapeutics in the 4th quarter valued at about $63,000. Teacher Retirement System of Texas purchased a new position in Stoke Therapeutics in the 4th quarter valued at about $113,000. AlphaQuest LLC purchased a new position in Stoke Therapeutics in the 1st quarter valued at about $72,000. Finally, US Bancorp DE lifted its stake in Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after buying an additional 11,108 shares in the last quarter.

Insider Buying and Selling

In related news, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock worth $143,332 in the last three months. 11.30% of the stock is owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.